Kairos Pharma, Ltd. (KAPA) Research

Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company focused on developing innovative treatments for individuals battling cancer. Its therapeutic portfolio includes a range of antibodies and small molecules engineered to combat various malignancies, such as prostate, lung, and breast cancer, as well as glioblastoma. Initially incorporated in 2013 under the name NanoGB13, Inc., the enterprise officially adopted its current identity as Kairos Pharma, Ltd. in July 2016. The company's operations are headquartered in Los Angeles, California.

Market snapshot

Symbol
KAPA
Price
$0.43
Day change
-5.91%
Market cap
$9.2M
P/E ratio
-1.55x
52-week range
0.43-2.11
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Peer companies

  • Allarity Therapeutics, Inc. (ALLR)
  • BriaCell Therapeutics Corp. (BCTX)
  • CASI Pharmaceuticals, Inc. (CASI)
  • Cingulate Inc. (CING)
  • Clearside Biomedical, Inc. (CLSD)
  • Entero Therapeutics, Inc. (ENTO)
  • Lexaria Bioscience Corp. (LEXX)
  • Lixte Biotechnology Holdings, Inc. (LIXT)

Recent insider activity

  • Bhowmick Neil — A-Award (171756 shares) on 2025-10-08
  • Bae Hyun W. — A-Award (19084 shares) on 2025-10-08
  • Bae Hyun W. — A-Award (10000 shares) on 2025-09-16
  • Murali Ramachandran — A-Award (152672 shares) on 2025-10-08
  • Keyoung Hansoo Michael — A-Award (19084 shares) on 2025-10-08

Open Kairos Pharma, Ltd. (KAPA) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.